Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
NCT00073073 is a phase 2 interventional trial sponsored by Georgetown University. As of 21 Nov 2026, it is completed. It studies Exemestane in Breast Neoplasms. The registry lists an enrollment of 46 participants at 2 sites in 1 country. The registry lists a start date of 30 Nov 2003 and a primary completion date of 31 Dec 2011.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00073073 |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Georgetown University |
| Enrollment | 46 |
| Registered sites | 2 |
| Countries | 1 |
| Conditions | Breast Neoplasms |
| Drugs | Exemestane |
| Start | 30 Nov 2003 |
| Primary completion | 31 Dec 2011 |
| Study completion | 31 Dec 2011 |
| Last update posted | 17 May 2016 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Suparna B Wedam, M.D.
National Cancer Institute, National Institutes of Health
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Lombardi Cancer Center, Georgetown University
Washington D.C.
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00073073
Each answer restates registry values shown on this page.
What is NCT00073073?
NCT00073073 is a phase 2 interventional trial sponsored by Georgetown University. It studies Exemestane in Breast Neoplasms.
Who leads NCT00073073?
The registry names Suparna B Wedam, M.D. (principal investigator, National Cancer Institute, National Institutes of Health) as the overall official.
Where does NCT00073073 run?
The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00073073 study?
The registered drug and biological interventions are Exemestane.
When did NCT00073073 end?
The registry lists a primary completion date of 31 Dec 2011 and a study completion date of 31 Dec 2011. The sponsor last updated the record on 17 May 2016.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.